Atherosclerotic Cardiovascular Disease

High lipoprotein(a) measured during childhood was predictive of atherosclerotic CVD development during adulthood, according to an analysis of two cohorts published in Circulation.

Physician “nudges” via electronic health record prompts and peer comparison feedback improved statin prescription in the primary care setting for eligible patients compared with usual care, researchers reported.

Time-restricted eating was associated with improvements in cardiometabolic markers among adults with normal weight and overweight, according to a study published in The Journal of Clinical Endocrinology & Metabolism.

A deep-learning model using information from a single chest X-ray reliably predicted atherosclerotic CVD risk and statin eligibility when compared with a common risk calculator, researchers reported.

CHICAGO — In this Healio video exclusive, Dipti Itchhaporia, MD, FACC, FESC, discusses some of the late-breaking science presented at the American Heart Association Scientific Sessions.

Lipoprotein(a) levels of 67 mg/dL or more may be indicative of similar risk for premature MI as LDL of 180 mg/dL or more in patients with familial hypercholesterolemia, researchers reported.

CHICAGO — In adults with atherosclerotic CVD or a risk equivalent, twice-yearly inclisiran injections were associated with a 44% reduction in LDL that was sustained over 4 years with no new safety signals observed, researchers reported.

CHICAGO — Olpasiran, a small interfering RNA agent directed to the liver, yielded substantial and sustained reductions in lipoprotein(a) concentrations among patients with established atherosclerotic CVD in the phase 2 OCEAN(a)-DOSE study.

LDL reduction is the major focus in the primary and secondary prevention of atherosclerotic CVD.

BOSTON — The medical community is better equipped to combat residual CVD risk than previously, but prevention of residual risk should be tailored using a precision medicine approach, a speaker said at the Cardiometabolic Health Congress.